Advertisement
Screener

ARTELO BIOSCIENCES, INC. (ARTL) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

1.4 / 5 stars · 10/35 Roast Me

ARTELO BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period

ARTELO BIOSCIENCES, INC. (ARTL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 24.84 thousand shares for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2022-11-08

  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-09-30 was -323.96K shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-06-30 was 91.15K shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2022-03-31 was 257.65K shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2021-11-30 was 0.00 shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2020 was 26.17K shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2019 was 0.00 shares.
  • ARTELO BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2018 was 0.00 shares.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month
2022-09-30-323.96K shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
-232.81K shares
derived: sum of 2 quarters · filed 2022-11-08
24.84K shares
10-Q · filed 2022-11-08
2022-06-3091.15K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
348.80K shares
10-Q · filed 2022-08-09
2022-03-31257.65K shares
10-Q · filed 2022-05-12
2021-11-300.00 shares
10-Q · filed 2022-01-12
2021-05-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-12
0.00 shares
derived: sum of 2 quarters · filed 2021-07-12
0.00 shares
10-Q · filed 2021-07-12
0.00 shares
derived: sum of 4 quarters · filed 2021-07-12
2021-02-280.00 shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-13
0.00 shares
10-Q · filed 2021-04-13
0.00 shares
derived: sum of 3 quarters · filed 2021-04-13
0.00 shares
derived: sum of 4 quarters · filed 2021-04-13
2020-11-300.00 shares
10-Q · filed 2021-01-14
0.00 shares
derived: sum of 2 quarters · filed 2021-01-14
0.00 shares
derived: sum of 3 quarters · filed 2021-01-14
26.17K shares
derived: sum of 4 quarters · filed 2021-01-14
2020-08-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-04
0.00 shares
derived: sum of 2 quarters · filed 2020-11-04
26.17K shares
derived: sum of 3 quarters · filed 2020-11-04
26.17K shares
10-K · filed 2020-11-04
2020-05-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-07-13
26.17K shares
derived: sum of 2 quarters · filed 2020-07-13
26.17K shares
10-Q · filed 2020-07-13
26.17K shares
derived: sum of 4 quarters · filed 2020-11-04
2020-02-2926.17K shares
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-13
26.17K shares
10-Q · filed 2020-04-13
26.17K shares
derived: sum of 3 quarters · filed 2020-11-04
26.17K shares
derived: sum of 4 quarters · filed 2020-11-04
2019-11-300.00 shares
10-Q · filed 2020-01-14
0.00 shares
derived: sum of 2 quarters · filed 2020-11-04
0.00 shares
derived: sum of 3 quarters · filed 2020-11-04
2019-08-310.00 shares
derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-04
0.00 shares
derived: sum of 2 quarters · filed 2020-11-04
0.00 shares
10-K · filed 2020-11-04
2019-05-310.00 shares
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-15
0.00 shares
10-Q · filed 2019-07-15
2019-02-280.00 shares
10-Q · filed 2019-04-15
2018-08-310.00 shares
10-K/A · filed 2019-12-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
NextCure, Inc. (NXTC)United States$0.024B-0.15
Cocrystal Pharma, Inc. (COCP)United States$0.022B
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B